• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Amphastar Pharmaceuticals Inc.

    9/2/25 4:08:33 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001611286
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Amphastar Pharmaceuticals, Inc.
    SEC File Number
    001-36509
    Address of Issuer
    11570 SIXTH STREET
    RANCHO CUCAMONGA
    CALIFORNIA
    91730
    Phone
    909-980-9484
    Name of Person for Whose Account the Securities are To Be Sold
    Petersen Floyd F.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    UBS Financial Services, Inc.
    11 Madison Avenue
    4th Floor
    New York � NY � 10010
    50015450.004649507709/02/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/07/2022RSUIssuerCheckbox not checked50006/07/2022N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Floyd Peterson
    c/o 11570 SIXTH STREET
    Rancho Cucamonga � CA � 91730
    Common08/01/202550010415.75
    Floyd Peterson
    c/o 11570 SIXTH STREET,
    Rancho Cucamonga � CA � 91730
    Common06/02/202550012835.05
    Floyd Peterson
    c/o 11570 SIXTH STREET,
    Rancho Cucamonga � CA � 91730
    Common07/02/202550011733.95

    144: Remarks and Signature

    Remarks
    Date of Notice
    09/02/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/26/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ UBS Financial Services Inc, as attorney-in-fact for Floyd Petersen

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AMPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    8/12/2025$36.00Hold → Buy
    Needham
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    10/21/2022$36.00Buy
    Jefferies
    More analyst ratings

    $AMPH
    SEC Filings

    View All

    SEC Form 144 filed by Amphastar Pharmaceuticals Inc.

    144 - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    9/2/25 4:08:33 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    8/12/25 6:10:42 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.

    10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    8/7/25 4:43:01 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

    1/8/25 6:00:00 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/26/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/13/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amphastar Pharmaceuticals upgraded by Needham with a new price target

    Needham upgraded Amphastar Pharmaceuticals from Hold to Buy and set a new price target of $36.00

    8/12/25 7:45:35 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals downgraded by Analyst with a new price target

    Analyst downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $30.00

    5/12/25 8:19:14 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $36.00 from $66.00 previously

    2/4/25 6:58:07 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

    1/26/24 4:40:02 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

    12/27/23 4:38:39 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

    6/30/23 9:33:25 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Petersen Floyd F. sold $15,492 worth of shares (500 units at $30.98), decreasing direct ownership by 0.65% to 76,531 units (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    9/3/25 4:20:45 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Petersen Floyd F. sold $10,416 worth of shares (500 units at $20.83), decreasing direct ownership by 0.64% to 77,031 units (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    8/4/25 7:17:46 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gaugh David Russell was granted 6,304 shares (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    7/22/25 4:23:29 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Financials

    Live finance-specific insights

    View All

    Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

    1/8/25 6:00:00 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/26/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/13/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    3/6/24 10:23:26 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    2/13/24 4:58:53 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    2/9/24 5:21:50 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care